Puberty blockers are sometimes prescribed to trans children who have not yet begun puberty to temporarily halt the development of secondary sex characteristics. Puberty blockers give patients more time to solidify their gender identity before starting puberty. While few studies have examined the effects of puberty blockers for transgender and
gender non-conforming adolescents, the studies that have been conducted generally indicate that these treatments are reasonably safe and can improve psychological well-being. Short-term side effects of puberty blockers include headaches, fatigue, insomnia, muscle aches, and changes in breast tissue, mood, and weight. The potential risks of pubertal suppression in
gender dysphoric youth treated with
GnRH agonists may include adverse effects on bone mineralization. Additionally, genital tissue in transgender women may not be optimal for potential
vaginoplasty later in life due to underdevelopment of the penis. Research on the long-term effects on brain development, cognitive function, fertility, and sexual function is limited. In the Netherlands, youth are allowed to begin taking cross-sex hormones at age 16, following their course of puberty blockers. Some studies support the ability of children to provide
informed consent for puberty blockers, arguing that if parents oppose a child's transition, the child may lack access to
medically necessary treatment. Comparisons have been drawn to the legal precedent allowing children of
Jehovah's Witnesses to receive blood transfusions despite parental objections. Research highlights the psychological benefits of puberty blockers and the potential psychological and physical harm resulting from lack of access. Transgender minors, particularly homeless transgender youth, who do not have standard access to blockers may seek them from unreliable sources, increasing the risk of dangerous side effects. Transgender youth have voiced support for their right to access puberty blockers. In
Bell v Tavistock, the
High Court of Justice of England and Wales ruled that it was unlikely that a child under the age of 16 could be
Gillick competent to consent to puberty-blocking treatment. This was overturned by the Court of Appeal, which ruled that children under 16 could consent to receiving puberty blockers. For those who are over 18 and do not require parental consent, there are several medical interventions available. For those wishing to transition from male to female, options consist of
facial feminization surgery, vaginoplasty,
breast augmentation surgery, and
cross-sex hormones. For those wishing to transition from female to male, options consist of
penile construction surgery,
breast reduction surgery, and cross-sex hormones. Under American Psychiatric Association criteria, in order for any individual to receive these medical treatments, they must have a written diagnosis of gender dysphoria and have undergone up to a year's worth of therapy. Citizens of
Malta can change their gender marker through a relatively simple paperwork process. In the United States, changing a gender marker typically requires medical documentation and may require individuals to return to their home state to obtain various legal documents. To update an existing gender marker and name, applications can be submitted for
driver's licenses and banking documents. In February 2024, the
American Psychological Association approved a policy statement supporting unobstructed access to health care and evidence-based clinical care for trans, gender-diverse, and nonbinary children, adolescents, and adults. The statement also opposes state bans and policies intended to limit access to such care. The British
Cass Review, which examined gender services for trans youth in the United Kingdom, stated in its systematic review of the literature that "the quality of the studies was not good enough to draw any firm conclusions, so all results should be interpreted with caution". However, other countries, including the United States, France, Canada, Australia, Germany, Switzerlands, Austria, and Japan, have disagreed with this conclusion through statements from relevant medical organizations, systematic reviews of their own, or subsequently released medical guidelines. In May 2025, a two year systematic review commissioned by the state of Utah as part of a ban on trans youth healthcare concluded that "The consensus of the evidence supports that the treatments are effective in terms of mental health, psychosocial outcomes, and the induction of body changes consistent with the affirmed gender in pediatric [gender dysphoria] patients. The evidence also supports that the treatments are safe in terms of changes to bone density, cardiovascular risk factors, metabolic changes, and cancer". The review's findings were thereafter dismissed by the Utah state legislature, who kept the ban in place. ==Vulnerability==